Hugel's hyaluronic acid filler product wins sale approval in China
Published: 19 Apr. 2022, 14:25
Hugel logo
With permission from China's National Medical Products Administration, the product will be sold under the name Persnica.
Distribution will be handled by Beijing-based Sihuan Pharmaceutical.
The move comes about two years after Hugel gained approval for its Letybo botulinum toxin product in China, marking a first for a Korean company.
The hyaluronic acid filler market is rapidly growing and becoming more competitive.
The size of the Chinese hyaluronic acid filler market, which was around 950 billion won ($770 million) in 2020, is expected to grow to 1.93 trillion won in 2023, and 3 trillion won in 2025, according to Hugel.
"Hugel's hyaluronic acid filler product, recognized for its quality, has been growing fast in the global market including the European market," said a spokesperson for Hugel. "We will endeavor to make it the best filler product in China."
BY SARAH CHEA [[email protected]]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)